• Daniela Calina, Anca Oana Docea, Demetrios Petrakis, Alex M Egorov, Aydar A Ishmukhametov, Alexsandr G Gabibov, Michael I Shtilman, Ronald Kostoff, Félix Carvalho, Marco Vinceti, Demetrios A Spandidos, and Aristidis Tsatsakis.
• Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
• Int. J. Mol. Med. 2020 Jul 1; 46 (1): 3-16.

AbstractIn the current context of the pandemic triggered by SARS-COV-2, the immunization of the population through vaccination is recognized as a public health priority. In the case of SARS‑COV‑2, the genetic sequencing was done quickly, in one month. Since then, worldwide research has focused on obtaining a vaccine. This has a major economic impact because new technological platforms and advanced genetic engineering procedures are required to obtain a COVID‑19 vaccine. The most difficult scientific challenge for this future vaccine obtained in the laboratory is the proof of clinical safety and efficacy. The biggest challenge of manufacturing is the construction and validation of production platforms capable of making the vaccine on a large scale.

33 keywords...

hide…